Department of Respiratory Medicine, Nanjing Chest Hospital , Nanjing , China and.
Biomarkers. 2014 Jun;19(4):287-90. doi: 10.3109/1354750X.2014.908954. Epub 2014 Apr 14.
The aim of this study was to explore the clinical role of serum interleukin (IL)-17 in patients with non-small-cell lung cancer (NSCLC).
Serum specimens from 128 patients with NSCLC and 60 healthy controls were collected. The concentrations of IL-17 were measured using enzyme-linked immunosorbent assay.
Serum IL-17 levels were higher in the NSCLC group in comparison with the control group (p < 0.01). With a cut-off value of 16 pg/ml, IL-17 showed a good diagnostic performance for NSCLC. Multivariate survival analysis indicated that IL-17 was an independent prognostic factor in NSCLC.
Measurement of IL-17 might be a useful diagnostic and prognostic value for patients with NSCLC.
本研究旨在探讨血清白细胞介素（IL）-17 在非小细胞肺癌（NSCLC）患者中的临床作用。
收集了 128 例 NSCLC 患者和 60 例健康对照者的血清标本。采用酶联免疫吸附试验检测 IL-17 浓度。
与对照组相比，NSCLC 组血清 IL-17 水平更高（p<0.01）。以 16pg/ml 为截断值，IL-17 对 NSCLC 具有良好的诊断性能。多变量生存分析表明，IL-17 是非小细胞肺癌的独立预后因素。
检测 IL-17 可能对 NSCLC 患者具有一定的诊断和预后价值。
